Silence Therapeutics discloses interim CEO pay and new director committee roles

Silence Therapeutics plc

Interim CEO Iain Ross receives £25,000/month cash for six months, then month-to-month, plus 900,000 option shares vesting over 12 months.
New director James Ede-Golightly appointed to Remuneration, Audit & Risk, and Nominations Committees; granted 90,000 option shares vesting over 12 months.
Ross is also eligible for a discretionary cash bonus as determined by the Remuneration Committee.
Both option grants are under the company's 2023 Equity Incentive Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.